Treatment with von Willebrand factor concentrates is generally well tolerated.1, 2
Rare cases of thromboembolic events or the development of alloantibodies have been reported with some von Willebrand factor concentrates.3, 4 No thromboembolic events or inhibitory alloantibodies have been reported in clinical trials with wilate® in people with all von Willebrand disease types.5
Tolerability of wilate® has been demonstrated across 8 clinical trials in 155 patients with von Willebrand disease5 *
With 28 treatment-related adverse events reported in 17 patients
* Indication: Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.
Thromboembolic events
Treatment-related deaths
Inhibitory antibodies to von Willebrand factor
Tolerability of wilate® was rated very good or good >99% of infusions6
Tolerability has been confirmed in over 15 years of experience in the real-world setting, with approximately 1.8 billion international units of wilate® distributed wordwide5
Information about on-demand treatment with wilate®
Surgical prophylaxis with wilate®
wilate® physiological 1:1 activity ratio
The information on this website is not country specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Octapharma representative for the latest information specific to your country.
Please contact your local Octapharma representative for local prescribing information via our contact form.
IMPORTANT
The information on this website is based on the European Summary of Product Characteristics (EU SmPC). US HCPs and other country-specific websites: Below is a list of countries that host a local wilate® website based on local approved information and in local language. Click on the country link to be redirected to the local wilate® website.
The website is provided by Octapharma AG, Seidenstrasse 2, 8853 Lachen, Switzerland
www.octapharma.com
© 2024 Octapharma AG